NASDAQ: MBOT Microbot Medical Inc. 8-K

Microbot Medical reports first LIBERTY System revenue in Q1, Q2 already exceeds Q1 total

Filed May 14, 2026 · Period ending May 14, 2026 · ~1 min read

Key Changes

  • high

    Company generated first revenue from LIBERTY Endovascular Robotic System during Q1 2026 limited market release, marking commercial launch of flagship product.

    Item 7.01 verify on EDGAR →
  • high

    Q2 2026 revenue has already surpassed entire Q1 total following transition to full market release, with accelerating adoption across multiple sales territories.

    Item 7.01 verify on EDGAR →

This preview is just the start — the full report includes the narrative summary, section-by-section diffs against the prior filing, and verbatim quotes with EDGAR citations.

Read 3 full reports/month free No card required. Takes 30 seconds.

Want to see a complete report first? Today's free report (HOTH 10-Q) is open in full — no account needed.

Partner

Trade MBOT commission-free

Open an account, get a free stock.

Sign up

Investing involves risk. Free stock terms apply.

View original filing on SEC.gov

Generated by AI · Jun 10, 2026 9:39 PM